GlassScriptPhysician profile
Todd A Goodglick
NPI 1053315036
$248,358.08
in general payments reported to CMS, 2019-2025
5 companies · $18K in 2025
The $18K reported for 2025 was more than what 95% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19K · 2021: $151K · 2022: $16K · 2023: $27K · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Honoraria: $24K · Consulting Fee: $6,300 · Travel and Lodging: $5,167 · Food and Beverage: $2,261 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,675.00 |
| Honoraria | $23,662.50 |
| Consulting Fee | $6,300.00 |
| Travel and Lodging | $5,166.79 |
| Food and Beverage | $2,261.45 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $138,189.17 | 2021 | |
| Horizon Therapeutics Plc | $74,960.87 | 2020-2023 | Tepezza |
| Amgen INC. | $35,094.23 | 2024-2025 | Tepezza |
| Catalyst Pharmaceuticals, INC. | $62.47 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $51.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Goodglick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.